- Home
- ILLR vs IMMX Comparison
ILLR vs IMMX Comparison
Compare ILLR & IMMX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ILLR
- IMMX
- Stock Information
- Founded
- ILLR 2015
- IMMX 2014
- Country
- ILLR United States
- IMMX United States
- Employees
- ILLR N/A
- IMMX N/A
- Industry
- ILLR Investment Managers
- IMMX Medicinal Chemicals and Botanical Products
- Sector
- ILLR Finance
- IMMX Health Care
- Exchange
- ILLR Nasdaq
- IMMX Nasdaq
- Market Cap
- ILLR 79.7M
- IMMX 65.5M
- IPO Year
- ILLR N/A
- IMMX 2021
- Fundamental
- Price
- ILLR $0.55
- IMMX $2.19
- Analyst Decision
- ILLR
- IMMX Strong Buy
- Analyst Count
- ILLR 0
- IMMX 1
- Target Price
- ILLR N/A
- IMMX $7.00
- AVG Volume (30 Days)
- ILLR 1.4M
- IMMX 255.8K
- Earning Date
- ILLR 09-02-2025
- IMMX 08-08-2025
- Dividend Yield
- ILLR N/A
- IMMX N/A
- EPS Growth
- ILLR N/A
- IMMX N/A
- EPS
- ILLR N/A
- IMMX N/A
- Revenue
- ILLR $45,244,000.00
- IMMX N/A
- Revenue This Year
- ILLR N/A
- IMMX N/A
- Revenue Next Year
- ILLR N/A
- IMMX N/A
- P/E Ratio
- ILLR N/A
- IMMX N/A
- Revenue Growth
- ILLR N/A
- IMMX N/A
- 52 Week Low
- ILLR $0.40
- IMMX $1.26
- 52 Week High
- ILLR $6.52
- IMMX $3.20
- Technical
- Relative Strength Index (RSI)
- ILLR 49.01
- IMMX 39.38
- Support Level
- ILLR $0.50
- IMMX $2.11
- Resistance Level
- ILLR $0.57
- IMMX $2.39
- Average True Range (ATR)
- ILLR 0.07
- IMMX 0.21
- MACD
- ILLR 0.01
- IMMX -0.03
- Stochastic Oscillator
- ILLR 52.14
- IMMX 9.52
About ILLR Triller Group Inc. Common Stock
Triller Group Inc is a us-based company that operates its businesses through Triller Corp which operates as a technology platform and AGBA Group Holding Limited operates as an insurance and wealth distribution platform.
About IMMX Immix Biopharma Inc.
Immix Biopharma Inc is engaged in the discovery and development of novel cell therapies for hematologic malignancies (blood cancers) and other indications. It is a clinical-stage biopharmaceutical company developing a novel class of Tissue-Specific Therapeutics TM in oncology and inflammation. Its TME Normalization Technology allows drug candidates to circulate in the bloodstream, exit through tumor blood vessels and simultaneously attack all components of the TME. Its product candidates include CAR-T NXC-201 for autoimmune diseases, and IMX-110 for treatment of soft tissue sarcoma.